P822: A PHASE 1 SINGLE ASCENDING DOSE STUDY OF CAN106, A LONG-ACTING ANTI-C5 COMPLEMENT MONOCLONAL ANTIBODY IN CLINICAL DEVELOPMENT FOR PNH AND OTHER COMPLEMENT-MEDIATED DISEASES
C. M. KHOO,
X. SONG,
Q. WU,
G. F. COX
Affiliations
C. M. KHOO
1 Department of Medicine, National University Hospital, Singapore, Singapore
X. SONG
2 Clinical Development and Medical Affair, CANbridge Pharmaceuticals Inc., Shanghai, China
Q. WU
2 Clinical Development and Medical Affair, CANbridge Pharmaceuticals Inc., Shanghai, China
G. F. COX
3 Clinical Development and Medical Affair, CANbridge Pharmaceuticals Inc., Cambridge, MA, United States of America
